Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference - Fast Track Designation granted from U.S. Food and Drug Administration for PRA023 for the treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - - New patent granted for...

Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery,...